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Abstract 
 
The emerging genomic technologies and bioinformatics provide novel opportunities for 
studying life-threatening human pathogens and to develop new applications for the 
improvement of human and animal health and the prevention, treatment, and diagnosis of 
infections. Based on the ecology and population biology of pathogens and related organisms 
and their connection to epidemiology, more accurate typing technologies and approaches will 
lead to better means of disease control. The analysis of the genome plasticity and gene 
pools of pathogenic bacteria including antigenic diversity and antigenic variation results in 
more effective vaccines and vaccine implementation programs. The study of newly identified 
and uncultivated microorganisms enables the identification of new threats. The scrutiny of 
the metabolism of the pathogen in the host allows the identification of new targets for anti-
infectives and therapeutic approaches. The development of modulators of host responses 
and mediators of host damage will be facilitated by the research on interactions of microbes 
and hosts, including mechanisms of host damage, acute and chronic relationships as well as 
commensalisms. The study of multiple pathogenic and non-pathogenic microbes interacting 
in the host will improve the management of multiple infections and will allow probiotic and 
prebiotic interventions. Needless to iterate, the application of the results of improved 
prevention and treatment of infections into clinical tests will have a positive impact on the 
management of human and animal disease.  
 
The Pathogenomics Research Agenda draws on discussions with experts of the Network of 
Excellence “EuroPathoGenomics” at the management board meeting of the project held 
during 18 – 21 April 2007, in the Villa Vigoni, Menaggio, Italy. Based on a proposed 
European Research Agenda in the field of pathogenomics by the ERA-NET PathoGenoMics 
the meeting’s participants updated the established list of topics as the research agenda for 
the future. 
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1. Introduction 
Bacterial infections remain a major cause of disease and mortality in humans and 
animals throughout the world. Only the detailed understanding of their pathogenic processes 
will provide the innovative tools for their treatment, prevention and eradication. New concepts 
laid down in this Research Agenda contribute to a global policy of control of infections both in 
Europe and in the developing world. Several infections constitute novel and particularly 
onerous threats owing to the occurrence of new virulent strains and the development of 
antibiotic resistances. Innovations in diagnostic techniques and therapy, as well as the 
development of vaccines against pathogenic microorganisms, are expected to come out of 
the joint research activities recommended in the European Research Agenda in the field of 
pathogenomics. 
Global approaches require technical platforms (i.e. genomics, microarrays, proteomics, 
imaging, structure, novel bioassays) that exceed the capacities of individual laboratories or 
institutions including the adaptation of international standards (i.e. MIAME (Gene 
expression), MIAPE (proteomics), MIARE (RNAi)). To that end, this proposed agenda will 
join together established European groups of the Network of Excellence 
“EuroPathoGenomics” as well as the ERA-NET PathoGenoMics to foster the development of 
new multidisciplinary paradigms in the study of infectious diseases.  
 
2. The Microbes 
 
In order to enable the development of novel diagnostic tools, therapeutic agents and 
vaccine candidates it is necessary to characterize the molecular and cellular basis of 
infection caused by bacterial pathogens. Therefore, the following methods, techniques and 
research topics on microorganisms constitute the focus of the agenda: 
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2.1 Genomic Tools and Comparative Genomics 
 
The application of genomic tools (e.g. metagenomics, sequence based typing) allows 
the examination of microbial ecology and population biology of pathogens and related 
organisms. Sequence based typing enables the analysis of genetic variation within microbial 
species (Brehony et al., 2007; Gutierrez et al., 2006). The understanding of horizontal gene 
transfer and recombination as common mechanisms in bacterial populations leading to high 
variability in genome size and gene content will be utilized as better means of disease control 
as well as for the identification and prediction of potential emerging pathogens. The use of 
metagenomics (Fig. 1) and metabolomics to analyse the diversity and potential activity of 
microbial populations will contribute to our understanding of highly prevalent, but previously 
unknown, metabolic processes in natural microbial communities that can be used for the 
development of new targets for anti-infectives and therapeutic treatment. The further 
development and improvement of sequencing and metagenomic as well as metabolomic 
technologies is a prerequisite for future research, applications and novel diagnostic 
approaches in the field of pathogenomics. 
 
Genome studies allowed the discovery of a wealth of unknown genes that may become 
targets for interfering with metabolism and signalling pathways. The improved understanding 
of the importance of metabolic traits for the viability and colonisation ability of bacterial 
pathogens within their hosts will lead to the identification of suitable metabolic targets and 
pathways. In particular, pathways that may be specific for groups of bacteria or single 
species would be promising metabolic targets to explore their interference with growth or 
survival of bacteria within the host and to develop novel drug targets. 
 
Furthermore, the identification of unculturable microorganisms from the commensal 
flora of the host and the environmental reservoir with culture-independent methods, such as 
PCR amplification from microbial community DNA (metagenome) and functional or 
sequence-based screening of metagenomic DNA libraries will contribute to the description of 
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complex bacterial communities, the dissection of environmental ecosystems and the 
biotechnological exploitation of this vast gene pool.  
 
To facilitate the identification of antigenic diversity and variation, genomes of 
pathogens will be compared with those of non-pathogenic related strains. Genomes of 
isolates to be studied will be compared with reference genomes (i.e. completely sequenced 
genomes). Genomic variability and antigenic diversity of pathogenic strains will also be 
addressed by analysing single nucleotide polymorphisms (SNPs) and by microarrays 
representing whole-genomes of diverse species or strains. Comparative genomics will lead 
to a better understanding of the mechanisms underlying bacterial variability responsible for 
ongoing evolution of bacterial antigenic diversity. Prominent examples already applied 
successfully to comparative genomics are the studies of different Listeria (Hain et al., 2007) 
and E.coli (Brzuszkiewicz et al., 2006) species.  The entire genome of corresponding model 
organisms has been sequenced and compared with the genome sequence of different 
representative strains of the genus. In the genus Listeria, genome reduction has led to the 
generation of non-pathogenic species from pathogenic progenitor strains. It has been shown 
that genomic differences between uropathogenic E. coli are mainly restricted to large 
pathogenicity islands.    
 
The knowledge of antigenic variations will allow the development of vaccines to tackle the 
pathogenetic mechanism of molecular mimicry of infectious bacteria associated with 
autoimmune disease. 
 
Many pathogens become increasingly resistant to available drugs and antibiotics. The 
prevalence of antibiotic resistances is increasing in developed as well as in developing 
countries. They impose an important socio-economic burden to the public, industry and the 
health care system. Therefore, comparative genomics will be used for a better understanding 
of genome plasticity, gene pools, the transfer of virulence and resistance determinants as 
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well as the development of new treatment and prevention strategies to reduce hospital 
infections.  
 
2.2 Evolution of Microbial Pathogens and Antibiotic Resistances 
Horizontal gene transfer is a topic of major health concern and is implicated in the 
spread of virulence-associated and antibiotic resistance genes among bacteria contributing 
to the evolution of bacterial pathogens (Wright, 2007). Using Gram-negative (e.g. extended-
spectrum-β-lactamase-resistant E.coli) and Gram-positive (e.g. Vancomycin-resistant 
Enterococci, Methicillin-resistant Staphylococci) model systems, different aspects of the 
evolution of microbial virulence and spread of antibiotic resistances will be studied by 
comparative genomics and functional studies. 
 
The mechanisms conferring the development and spread of antibiotic resistances among 
bacteria as well as the bacterial gene expression in response to the exposure to antibiotics 
will be investigated in order to get a deeper insight into the effect of antibiotics on gene 
regulation. These approaches will result in an improved understanding of the molecular 
mechanisms contributing to the development and spread of antibiotic resistances and to the 
discovery of novel anti-infectious agents and their targets. 
 
Research at the molecular level on the influence of lifestyle and environmental 
conditions on genome plasticity and variability of bacterial pathogens will elucidate the 
mechanisms involved in transfer and mobilisation of antibiotic resistance genes between 
different bacterial strains. The improved understanding of triggering stimuli and the molecular 
mechanisms underlying genomic variability and the evolution of microbial virulence and 
antibiotic resistances will allow the development of comprehensive diagnostic tools which will 
enable an effective therapy adapted to the individual patients’ situation (Fig. 2). 
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2.3 Microbe-Microbe Interactions 
Microbial communities such as biofilms are involved in many infections in humans, 
often resulting in chronic states that are very difficult to combat (Reisner et al., 2005). Control 
of biofilm formation (Fig. 3) is therefore a major concern with both important health and 
economic issues. One of the main aims is to characterize biofilm aspects of important 
infections, e.g. Staphylococcus epidermidis and Pseudomonas aeruginosa, by studying the 
general physiological properties of bacteria associated with biofilm infections. Single 
pathogenic bacterial biofilms based on model systems for serious human infections will be 
developed and used to analyze their general phenotypic properties and gene expression 
profiles.  
As it has been shown that the presence of specific genes and surface proteins is important 
for biofilm formation (Beloin et al., 2006; Valle et al., 2007), the characterization of the 
genetic basis and the expression profile of pathogenic bacterial biofilm formation as well as 
microbe-microbe interaction will lead to the identification of further factors expressed within 
biofilms. These factors will be utilized for the development of new strategies for diagnosis, 
prevention and control of microbial infections.  
 
 
3. Host-Microbe Interactions 
 
The complex interaction between a microbial pathogen and a host (Fig. 4) is the 
underlying basis of the infectious disease. The understanding of the molecular and cellular 
details of these host-microbe interactions may lead to the identification of virulence-
associated microbial genes and host-defence strategies. This information will be used for the 
design of a new generation of medical tools. 
 
3.1 Metabolic Interactions, Gene Expression and Adaptation Processes 
Major pathogens have developed a variety of strategies with which they adapt their 
genetic expression to meet the challenges of their ever-changing surrounding environment, 
e.g. within the host cell. These include specific sigma factors, two-component systems, 
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repressors, positive regulators, as well as small regulatory RNAs. Alone or in combination, 
these functions enable bacterial cells to communicate with their environment, their hosts, and 
with each other, allowing the bacteria to adopt specific responses, express specific proteins  
(toxins, adhesins, invasins, siderophores) or develop specialized structures such as biofilms 
or spores to ensure survival, colonisation of their ecological niches and dissemination. 
Studies of these metabolic interactions and adaptations in both the bacteria and the host cell 
will lead to a better understanding of the mutual reactions in the course of infection. 
 
The aim is to carry out an extensive analysis of the gene activity of infected hosts and 
microbes during the course of infection. Studies on regulatory networks involved in the 
production of virulence factors and survival of pathogens in vitro and within the host will be 
accomplished by whole genome expression profiling using DNA arrays, expression studies 
and reporter gene fusions. Random mutagenesis or overexpression of genes will also be 
used in combination with proteome analysis. Furthermore, protein-protein interaction 
mapping will be undertaken as well to define the structure of complex regulators and 
regulons. Besides a better knowledge of the molecular mechanisms essential for host 
responses and virulence, the discovery of new targets for antimicrobial compounds is 
expected. 
 
Pathogenic microorganisms must be able to adapt to changing environmental 
conditions to ensure survival and growth in different host niches. This adaptation is achieved 
by the regulated expression of appropriate sets of genes whose products are needed by the 
pathogen at a particular stage of an infection in response to corresponding environmental 
signals. During chronic infection pathogen adaptation to specific host habitats can occur by 
conversion to mutator state (e.g. mismatch repair deficiency in Pseudomonas aeruginosa) 
resulting in hypervariability of the genome (Hogardt et al., 2007). In addition, many 
pathogens have the capacity to generate variants with altered properties and to express 
certain products in a ‘phase-variation’ mode. Such variability enables evasion from the innate 
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and adaptive host immune defences, e.g. Bacillus anthracis (Baldari et al., 2006), 
Staphylococcus aureus (van Belkum, 2006). The study of these evasion mechanisms and 
the development of technologies to analyse infections and corresponding gene expression 
on the single cell level will elucidate bacterial adaptation processes. For example, 
asymptomatic E.coli carrier strains in urinary tract infections (Fig. 5) are capable of evading 
the innate immune responses. These strains are adapted for growth and carry virulence 
genes that are not expressed (Svanborg et al., 2006). 
 
3.2 Host Susceptibility and Interference with Host Cell Functions  
 
Microbial organisms may suddenly emerge as disease threats by acquiring new 
capacities for initiating infections and disease or by altering the host's natural ability to mount 
an effective immune response. From the perspective of the host, non-specific factors as well 
as inherent factors related to host susceptibility or resistance, provide strategies of resistance 
to the changing patterns of microbial infectivity and virulence. Thus, infection and immunity 
are always in a dynamic balance determined by characteristics of both the pathogen and the 
host. The study of the requirements to shift this balance between health and disease will lead 
to the knowledge of corresponding predictive markers. Mycobacterium tuberculosis is a 
prominent example of such bacteria that have the ability to modulate and manipulate the host 
immune system. Therefore, improved identification of predictive markers for quick, accurate 
and early detection of such bacteria will strengthen the efforts to combat bacterial pathogens 
(Chakhaiyar et al., 2004, Banerjee et al., 2004). 
 
Research on infections caused by pathogenic micro-organisms (bacteria, fungi) with 
the capacity of affecting human health is to be extended using the in vivo natural setting. In 
order to prevent infections, methods to interfere with host cell functions, e.g. by usage of 
RNA interference (RNAi) in the course of acute and chronic infections will be applied. 
Examples include acute bacterial sepsis and meningitis, characterized by an overwhelming 
host response, and chronic chlamydial infections with a potential of secondary pathologies. 
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In the future, a global screening and analysis of host cell functions will enable the 
assessment of identified host cell functions in the living animal using in vivo RNAi and the 
development of treatment regimens. However, any in vivo studies and potential treatment 
options require prior knowledge of host cell factors, displaying essential functions in the 
infection process. RNAi-based loss-off-function strategies promise to give such insights, 
particularly with respect to the primary host cell targets of infectious agents as well as the 
crucial host defence machinery. 
 
2.3 Cellular Microbiology 
The epithelial and endothelial surfaces of hosts form a physical barrier that is 
impermeable to most infectious agents. However, some bacteria have developed 
mechanisms to break these barriers (e.g. connective tissue, blood-brain barrier, gut 
epithelium, pulmonary epithelium, placenta) provoking severe infections. Elucidation of these 
mechanisms will lead to further knowledge on how to prevent the breakage of the first line of 
defence against microorganisms. These studies include the following topics:  
receptors and cell surface structures of the host cell; cell and tissue tropism; bacterial cell 
surface structures; cell-cell communication; specific target ligand design. 
 
3.4 Commensal Flora, Mixed and Nosocomial Infections 
Both humans and animals have a multitude of microenvironments such as the intestine, skin 
and dental cavities that are populated by phylogenetically complex microbial communities. 
To assess the role of the commensal flora as a protective barrier against invading pathogens 
but also as a reservoir for the recruitment of new emerging infectious diseases, it is important 
to elucidate how commensal organisms or probiotics can be used to prevent or treat 
infections. The evaluation of host response patterns upon exposure to a single pathogen vs. 
commensal flora will contribute to the understanding of the interactions of the resident flora 
with the host, the relation between pathogenic and non-pathogenic species as well as the 
interactions among pathogens themselves. We can predict that in a near future, it will be 
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shown that many gastrointestinal disorders have bacterial components of etiology. Further 
efforts are required to analyze the communication between the intestinal cells and the 
resident flora. 
The topic of secondary pathologies such as chronic infections, cancer and autoimmune 
diseases that may also be triggered by microorganisms as well as persistent asymptomatic 
infections established by selected bacterial pathogens, such as Helicobacter pylori and 
Mycobacterium tuberculosis, in mammalian hosts will also be under scrutiny in the future. 
 
Although not a general phenomenon, some pathogens exacerbate the effects of 
others. Outstanding examples are the potentiation of bacterial infections by existing viral 
infections. Co-infections involving various combinations of pathogens are frequently 
described, and some tend to be particularly severe. Diseases caused by mixed Papilloma 
virus-Chlamydia (Finan et al., 2006), HIV-Mycobacteria (Djoba Siawaya et al., 2007) and 
Influenza-Staphylococcus infections are major examples of these so-called mixed infections 
that will also be in the focus of the Research Agenda.  
 
Natural and acquired factors are leading to resistance to antimicrobials of nosocomial 
bacteria. Production of inactivating enzymes is the most common mechanism in Gram-
negative bacteria. In Gram-positive bacteria, the main mechanism involves modifications in 
the bacterial targets of antimicrobials. The presence of other mechanisms is common, and as 
a result many nosocomial strains are multiresistant. Therefore, the study of underlying 
mechanisms is required to overcome bacterial resistance strategies involving novel 
diagnostic and therapeutic approaches. 
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4. Development and Improvement of Tools for Research and Application 
 
In order to identify novel targets for the eradication of and vaccination against 
pathogens new tools, methods and bioassays as well as novel diagnostic approaches and 
new in vitro screening techniques (e.g. small bioactive molecules) have to be developed and 
improved for research and application. 
 
4.1 New Imaging Techniques 
To gain further insights into the dynamic processes occurring in vivo and to be able to 
visualize and follow infections within the host, bioluminescence and other imaging techniques 
are required. Suitable imaging techniques will be established and used to study infectious 
processes in living cells, tissues and hosts and to address questions concerning cell biology, 
cell/tissue organisation and localisation of pathogens in vivo. Bacterial strains to be 
scrutinized will be tagged (construction of reporter strains) with appropriate markers in order 
to enable their three dimensional visualisation within the living cells, tissues and hosts. The 
pathogen-host interaction, e.g. dynamics of the host cell cytoskeleton and membrane 
trafficking upon invasion of intracellular bacteria, will then be followed by different dynamic 
microscopic and imaging techniques including confocal microscopy and bioluminescence 
digital imaging. Furthermore, these techniques will allow the bioluminescent measurement of 
biological activities (e.g. promoter activities) inside cells and/or tissues and the localisation of 
virulence factors, toxins and whole bacteria in host tissues. For example, the localisation of 
Staphylococcus aureus during the infection of soft tissue in the mouse has already been 
demonstrated successfully (Fig. 6). 
 
The usage of structural biology as a tool to study host-microbe interactions on the 
molecular basis will enable a detailed understanding of microbial effectors and of host cell 
targets at the molecular level. This strategy has already been used to reveal the structural 
basis for host tropism of Listeria monocytogenes (Schubert et al., 2002). The establishment 
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of relevant infection models and in vivo imaging will allow the detection and analysis of 
targeted cells. 
 
4.2 Transcriptome and Proteome Analysis 
In order to gain new insights into host responses of infected tissues, a new generation 
of microarrays (amongst others custom made commercial chips, protein arrays, bacterial 
clone arrays, cell arrays, lab on chip) and proteomics will be used to deal with the difficulties 
to integrate data from multiple experiments. Already accomplished analysis of regulatory 
networks involved in the production of virulence factors and survival of pathogens, e.g. 
Legionella (Brüggemann et al., 2006) and Pseudomonas (Ventre et al., 2006) will be 
continued. These innovations with DNA array analysis in pathogenomics and infectious 
disease will allow the development of excellent research tools for comparative genome 
analysis, typing of bacterial strains and diagnostics as well as the development of 
biomarkers. 
 
The transcriptome analysis of the microbe (regulating networks in vitro and in vivo) and the 
host (cellular and animal studies, human samples, e.g. blood) will allow the identification of 
novel virulence factors and new pathways specific for eukaryotic cell types, respectively. 
Furthermore, additional results will be achieved by combining bacterial and host transcription 
profiles and the integration of regulatory pathways and the cell cycle by the analysis of 
mutant strains. 
 
4.3 Development of Delivery Systems and Transgene Techniques 
The development of recombinant vaccines by the expression of foreign antigens in 
attenuated strains derived from bacterial pathogens and in non-pathogenic commensal 
bacteria aims to stimulate mucosal immunity (Schoen et al., 2004). Mucosal immunity 
represents the range of host defences that prevent the attachment and invasion of infectious 
disease agents at the body surfaces of the respiratory, digestive and reproductive tracts. As 
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the application of technologies for the generation of human vaccines is still limited, the 
development of new and improved bacterial delivery systems is required. 
 
The characterisation of host response to bacterial infection and the improved 
understanding of the role of eukaryotic (host) factors for infection require gene knock-out 
techniques as well as transgenic techniques. The effects of over-expression, inappropriate 
expression or lack of expression of specific eukaryotic genes will be studied in order to 
comprehend how their encoded products confer susceptibility and also in the infection 
process. Therefore, animal models by transgene techniques (e.g. lacking or expressing 
receptors of interest) will be used to study the importance of these receptors for infection of 
bacterial pathogens. 
 
4.4 Strain Collection and Databases 
The establishment of strain and tissue collections will facilitate and accelerate the 
exchange of biological material between researchers in the field of pathogenomics. In a 
future perspective, the collection of data and storage in central databases will allow rapid 
search and secure access to suitable biological material. 
 
The establishment of integrated databases (genome sequences, transcriptomes, 
proteomes) and data analysis techniques will lead to metabolic network reconstructions 
(network modelling) to understand how a microorganism functions inside of the host cell. The 
usage of predictions generated from metabolic reconstruction models will be applied for the 
development of novel drug delivery methods. 
 
In summary, the following technologies and infrastructure research will develop in the coming 
years which will play a decisive role in global efforts to combat infectious diseases both 
emerging and re-emerging: new bioassays; imaging techniques (bioluminescence); analysis 
of infections and gene expression on the single cell level; RNAi technologies; novel 
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diagnostic approaches; sequencing and metagenomics technologies; in vitro screening 
techniques; bacterial delivery systems; structural biology on the molecular basis; 
microarrays, proteomics of infected tissues; transgene techniques; strain and tissue 
collection; data analysis techniques. 
 
 
 
5. Outlook 
 
The study of microbial pathogenesis, parasitism, symbiosis, and commensalism is a large 
field of research requiring extensive expertise in many different domains, including genomics, 
epidemiology, immunology, cellular biology, and imaging techniques. To cover this field it is 
necessary to federate European capacities of important research centers, laboratories and 
industry. Therefore, the EU-funded projects Network of Excellence “EuroPathoGenomics” 
(NoE EPG) and ERA-NET PathoGenoMics evolved the European Research Agenda to 
establish an area of excellence in research on infectious diseases caused by bacterial 
pathogens. 
 
The implementation of the European Research Agenda will promote discoveries leading to: 
(a) the development of innovative diagnostic tools; (b) the discovery of novel anti-infectious 
agents and their targets; (c) the identification of new antigens, and (d) the deciphering of host 
defence mechanisms. The detection of suitable new targets for vaccination and therapy and 
the development of new vaccine candidates, therapeutic strategies and diagnostic tools for 
the identification of virulence factors, drug targets or vaccine candidates are the long-term 
goals expected from the joint efforts in the future. 
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Legend: 
 
Fig.1: Comparison of different E. coli genomes. Circles represent complete E. coli genomes. From 
inside to outside: E. coli K-12 strain MG1655, uropathogenic E. coli strain 536, uropathogenic E. coli 
strain CFT073, enterohemorrhagic E. coli strain EDL 933. The conserved E. coli gene pool is indicated 
in grey. Pathotype-specific genes are marked in red (UPEC) or green (EHEC). 
Source: E. Brzuszkiewicz, H. Brüggemann & U. Dobrindt 
 
Fig. 2: Genotyping DNA chip for the simultaneous assessment of antibiotic resistance and 
pathogenicity potential of extraintestinal pathogenic Escherichia coli (false colour fluorescence image). 
Source: T. Barl, T. T. Bachmann 
 
Fig. 3: Staphylococcus epidermidis biofilm formation. 
Source: H. Merkert 
 
Fig. 4: FISH (Fluoresence In Situ Hybridization) detection of human epithelial bladder cells (T24), 
Citrobacter freundii and Candida albicans. 
Source: H. Merkert 
 
Fig 5: S-Fimbriae expressing E.coli strain. 
Source: H. Merkert 
 
Fig. 6: Bioluminescence of Staphylococcus aureus in the subdermal infection model. The time course 
of bioluminescence was monitored for 5 consecutive days (d0 to d5) after subdermal infection of the 
lower back area of mice with 1x106 CFU S. aureus Xen29 (upper row) or 1x106 CFU S. aureus isaA 
deletion mutant (second row). Signal intensity is indicated by a pseudocolor scale.  
Source: K. Ohlsen 
 20
Figure 1: 
 
 
 21
Figure 2 
 
 
 22
Figure 3 
 
 
 23
Figure 4 
 
 
 24
Figure 5 
 
 
 25
Figure 6 
 
 
